Skip to main content
. 2021 Aug 13;83(5):573–580. doi: 10.1016/j.jinf.2021.08.019

Fig. 2.

Fig. 2

Seroprevalence in student (a) and staff (b) sKIDsPLUS participants by region using the Roche N and Roche S assays in Round 3 (March/April 2021) and compared to community estimates for N and S antibodies.

Source: NHSBT Seroprevalence data for the period 15th March to 11th April: * S antibody prevalence in 18–30 year olds by region; ^ N antibody prevalence in 18–30 year olds; # S antibody prevalence in 18–64 year olds by region; + N antibody prevalence in 18–64 year olds by region.